GlassScriptPhysician profile
Ana Raygoza
NPI 1437313913
$9,737.61
in general payments reported to CMS, 2019-2025
34 companies · $1,933 in 2025
The $1,933 reported for 2025 was more than what 92% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,665 · 2022: $2,361 · 2023: $1,716 · 2024: $2,063 · 2025: $1,933.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,712.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,712.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,744.02 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,879.35 | 2021-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $1,296.60 | 2021-2025 | Tremfya, Stelara, Remicade |
| Redhill Biopharma INC. | $491.74 | 2021-2023 | Talicia |
| Lilly USA, LLC | $354.36 | 2023-2025 | Omvoh |
| Qol Medical, LLC | $325.28 | 2021-2025 | Sucraid, Sucraid |
| Takeda Pharmaceuticals U.S.A., INC. | $301.30 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Pfizer INC. | $258.12 | 2021-2023 | |
| Nestle Healthcare Nutrition INC. | $245.30 | 2021-2023 | |
| Gilead Sciences, INC. | $217.15 | 2022-2025 | Livdelzi |
| Phathom Pharmaceuticals, INC. | $189.16 | 2024-2025 | Voquezna |
| Evoke Pharma, INC. | $179.05 | 2021-2025 | Gimoti |
| Ardelyx, INC. | $164.22 | 2022-2025 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $130.04 | 2021-2024 | Linzess |
| Celltrion USA INC. | $129.37 | 2024-2025 | Vegzelma |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $128.88 | 2024-2025 | Iqirvo, Bylvay |
| Merck Sharp & Dohme LLC | $86.67 | 2022-2024 | Dificid |
| Ferring Pharmaceuticals INC. | $86.11 | 2022-2023 | Rebyota |
| Aimmune Therapeutics, INC. | $79.96 | 2024-2025 | Zenpep |
| Vivus LLC | $55.80 | 2021-2025 | Pancreaze |
| Novo Nordisk INC | $54.42 | 2025 | Wegovy |
| Intercept Pharmaceuticals, INC. | $52.13 | 2021-2022 | |
| Medtronic, INC. | $42.93 | 2024-2025 | |
| Braintree Laboratories, INC. | $37.55 | 2022-2024 | Suflave |
| Janssen Pharmaceuticals, INC | $29.67 | 2022 | |
| Celgene Corporation | $27.88 | 2021-2023 | Zeposia |
| Genzyme Corporation | $26.80 | 2023-2024 | |
| Fresenius Kabi USA, LLC | $23.66 | 2024 | Idacio |
| American Regent | $18.82 | 2025 | Injectafer |
| Madrigal Pharmaceuticals | $17.54 | 2024 | Resmetirom |
| Shield Therapeutics INC | $17.11 | 2024 | |
| Azurity Pharmaceuticals, INC. | $16.13 | 2025 | Suflave |
| Regeneron Healthcare Solutions, INC. | $15.89 | 2022 | |
| Olympus America INC. | $14.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ana Raygoza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.